Making Pain Relief Affordable – Or Abuse Cheaper?
This article was originally published in RPM Report
There are many arguments against generics of opioids, especially if you’re Purdue Pharma. Here’s a new one: they’re lower the cost for abusers.
You may also be interested in...
FDA is showing a renewed commitment to meeting review deadlines for new molecular entities, but that is not translating into earlier commercial availability for all NMEs. Some products also need a controlled substance scheduling decision from the Drug Enforcement Administration; those actions have become a new regulatory purgatory that can be painful and frustrating.
New incentives will most likely not be the immediate focus, but working group to explore ideas on enhancing understanding of drug effects in elderly populations will likely be formed by US FDA.
New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.